Catherine Tralau-Stewart
Net worth: 4 113 $ as of 2026-07-30
Net worth: 4 113 $ as of 2026-07-30
Catherine Jane Tralau-Stewart is currently Executive Director at Milner Therapeutics Institute since 2023 and a Member of the British Pharmacological Society.
Former roles include Non-Executive Director at ValiRx Plc from 2025 to 2026 and Chief Scientific Officer at C4X Discovery Holdings Ltd. from 2022 to 2023.
Education includes undergraduate and doctorate degrees from UCL Medical School.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
VALIRX PLC 0.15% | 2025-11-20 | 2,035,897 ( 0.15% ) | 4 113 $ | 2026-07-30 |
| Companies | Position | Start |
|---|---|---|
British Pharmacological Society
British Pharmacological Society Investment Trusts/Mutual FundsMiscellaneous Provides charity services to promote the spectrum of pharmacology | Corporate Officer/Principal | - |
Milner Therapeutics Institute | Director/Board Member | 2023-03-31 |
| Companies | Position | End |
|---|---|---|
| VALIRX PLC | Chief Tech/Sci/R&D Officer | 2025-03-26 |
| C4X DISCOVERY HOLDINGS PLC | Chief Tech/Sci/R&D Officer | 2023-01-09 |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 5 |
|---|---|
ValiRx Plc
ValiRx Plc Pharmaceuticals: MajorHealth Technology Develops novel technologies and products in oncology therapeutics and diagnostics | Health Technology |
British Pharmacological Society
British Pharmacological Society Investment Trusts/Mutual FundsMiscellaneous Provides charity services to promote the spectrum of pharmacology | Miscellaneous |
C4X Discovery Holdings Plc
C4X Discovery Holdings Plc Pharmaceuticals: MajorHealth Technology Operates as a drug discovery company | Health Technology |
UCL Medical School
UCL Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Milner Therapeutics Institute |
Select your edition
All financial news and data tailored to specific country editions